According to MannKind Corp's latest financial reports the company's current revenue (TTM) is $0.19 B. In 2022 the company made a revenue of $99.77 M an increase over the years 2021 revenue that were of $75.44 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.19 B | 99.42% |
2022 | $99.77 M | 32.25% |
2021 | $75.44 M | 15.81% |
2020 | $65.14 M | 3.34% |
2019 | $63.03 M | 126.28% |
2018 | $27.85 M | 137.2% |
2017 | $11.74 M | -93.28% |
2016 | $0.17 B | |
2015 | N/A | |
2014 | N/A | |
2013 | N/A | -100% |
2012 | $0.03 M | -30% |
2011 | $0.05 M | -46.24% |
2010 | $0.09 M | |
2009 | N/A |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Pfizer PFE | $58.49 B | 29,301.09% | ๐บ๐ธ USA |
Novo Nordisk NVO | $33.81 B | 16,895.16% | ๐ฉ๐ฐ Denmark |
Eli Lilly LLY | $34.12 B | 17,051.06% | ๐บ๐ธ USA |
Merck MRK | $60.11 B | 30,113.81% | ๐บ๐ธ USA |
Halozyme Therapeutics HALO | $0.82 B | 316.79% | ๐บ๐ธ USA |
Nektar Therapeutics
NKTR | $90.12 M | -54.70% | ๐บ๐ธ USA |